Last updated: February 24, 2026
What is the Drug Associated with NDC 69238-1745?
NDC 69238-1745 is identified as Zolbetuximab (IMAB362), an investigational monoclonal antibody targeting CLDN18.2, developed primarily for the treatment of gastric and gastroesophageal cancers. It is in late-stage clinical trials, with no FDA-approved indication yet.
Current Development Status
- Phase: III trials, with some studies completed or nearing completion.
- Regulatory Handoff: No approval obtained; potential for submission depends on trial outcomes.
- Partnerships: Numerous collaborations with biotech firms and strategic investors.
Market Landscape
| Segment |
Details |
| Addressable Population |
Approximately 110,000 new gastric cancer cases worldwide annually |
| Competitive Drugs |
Trastuzumab, Ramucirumab, Pembrolizumab (approved in various gastric cancers) |
| Unmet Need |
Limited effective treatments for specific tumor subtypes expressing CLDN18.2 |
Market Size and Growth
- Worldwide gastric cancer treatment market was valued at ~$3.2 billion in 2021.
- Compound annual growth rate (CAGR): 6.4% (2022–2027).
- Immunotherapies and targeted therapies constitute the fastest-growing segments.
Price Projection Methodology
- Benchmarking against similar monoclonal antibodies: Trastuzumab historically priced at ~$3,000–$4,900 per month.
- Market penetration assumptions: Initially targeting high-expression gastric tumor subgroups.
- Pricing strategy: Likely premium, due to targeted mechanism and clinical trial investment.
Using these, initial wholesale acquisition cost (WAC) projections for Zolbetuximab are estimated at $7,000–$10,000 per treatment month.
Future Revenue Potential
| Scenario |
Approximate Revenue (2025-2030) |
Assumptions |
| Conservative |
$500 million |
15% market share, lower pricing, slower adoption |
| Moderate |
$1.2 billion |
25% market share, consistent growth, premium pricing |
| Optimistic |
$2 billion |
35% market share, rapid adoption, pricing near $10,000/month |
Competitive Risks and Challenges
- Meeting regulatory approval, contingent on trial results.
- Existing drugs with established reimbursement.
- Potential side effect profile limiting utilization.
- Market entry timing impacting penetration rates.
Price Erosion and Policy Impact
- Biosimilar development may reduce prices by 20–40% within five years post-approval.
- Payer pressure to negotiate discounts, especially in health systems with cost controls.
- Value-based pricing models likely to influence reimbursement levels.
Key Takeaways
- NDC 69238-1745 (Zolbetuximab) is an investigational therapy in late-stage clinical trials, with no FDA approval.
- The gastric cancer market presents a sizable opportunity, valued at over $3 billion globally.
- Price projections for initial launch could range from $7,000 to $10,000 per month.
- Market penetration will depend on clinical success, regulatory approval, and competitive positioning.
- Long-term revenue depends on trial outcomes, regulatory timelines, and competitive dynamics.
FAQs
1. When is Zolbetuximab expected to receive approval?
It depends on phase III trial outcomes; potential approval could occur within 1–2 years if trials are successful.
2. How does the price of Zolbetuximab compare to existing treatments?
It is projected to be priced higher initially due to targeting a specific biomarker and limited competition.
3. What factors influence the market penetration of new gastric cancer drugs?
Regulatory approval, clinical trial results, reimbursement policies, and physician adoption rates.
4. What are the key risks for investors in Zolbetuximab?
Clinical failure, regulatory delays, competitive displacement, and pricing pressures.
5. How might biosimilars impact the drug's pricing?
Biosimilar entry could reduce prices by up to 40% within five years, affecting revenue potential.
Sources
[1] Market Research Future. (2022). Gastric Cancer Treatment Market Forecast.
[2] IQVIA. (2022). Global Oncology Drug Trends.
[3] EvaluatePharma. (2022). Oncology Market Data.
[4] U.S. Food and Drug Administration. (2023). Drug Approval Pipeline.
[5] Statista. (2022). Oncology drug market size projections.
